Multiple myeloma in the young: insights on prognosis, clinical features and treatment outcome derived from nationwide German registry data and a nested multicenter sample

Autor: Abdulaziz Kamili, Paymon Ahmadi, Lisa Leypoldt, Franziska Marquard, Christoph Schaefers, Ricardo Kosch, Frederik Peters, Henrik Kusche, Tanja Zamrik, Christine Hanoun, Maximilian Seib, Evgenii Shumilov, Theo Leitner, Cyrus Khandanpour, Carsten Bokemeyer, Katja Weisel, Susanne Ghandili

Publikováno v: Haematologica, Vol 999, Iss 1 (2024)

Not available.

Externí odkaz: https://doaj.org/article/f0fa425206244bb2abb516ff50d98dbd

Outcome Prediction in Patients With Large B-cell Lymphoma Undergoing Chimeric Antigen Receptor T-cell Therapy

Autor: Conrad-Amadeus Voltin, Philipp Gödel, Laura Beckmann, Jan-Michel Heger, Carsten Kobe, Nadine Kutsch, Peter Borchmann, Markus Dietlein, Ken Herrmann, Matthias Stelljes, Kambiz Rahbar, Georg Lenz, H. Christian Reinhardt, Marcel Teichert, Richard Noppeney, Jörn C. Albring, Robert Seifert, Bastian von Tresckow, Sarah Flossdorf, Christine Hanoun

Publikováno v: HemaSphere, Vol 7, Iss 1, p e817 (2023)

The introduction of chimeric antigen receptor (CAR) T-cell therapy has led to a fundamental shift in the management of relapsed and refractory large B-cell lymphoma. However, our understanding of risk factors associated with non-response is still ins

Externí odkaz: https://doaj.org/article/00e11d7dcadb4ef1933acac43af2c1ef

Baseline PET radiomics outperforms the IPI risk score for prediction of outcome in diffuse large B-cell lymphoma

Autor: Jakoba Johanna Eertink, Gerben JC Zwezerijnen, Martijn Heymans, Simone Pieplenbosch, Sanne Elisabeth Wiegers, Ulrich Dührsen, Andreas Hüttmann, Lars Kurch, Christine Hanoun, Pieternella J. Lugtenburg, Sally Barrington, N. George Mikhaeel, Luca Ceriani, Emanuele Zucca, Sandor Czibor, Tamás Györke, Martine E.D. Chamuleau, Otto S Hoekstra, Henrica CW De Vet, Ronald Boellaard, Josée M. Zijlstra

Publikováno v: PETRA consortium 2023, ' Baseline PET radiomics outperforms the IPI risk score for prediction of outcome in diffuse large B-cell lymphoma ', Blood, vol. 141, no. 25, pp. 3055-3064 . https://doi.org/10.1182/blood.2022018558

The objective of this study was to externally validate the clinicalPET model developed in the HOVON-84 trial and to compare the model performance of our clinicalPET model to the international prognostic index (IPI). In total, 1195 Diffuse large B-cel

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f74bc5615f00026c832dbdc2f2ae1fcc
https://research.vumc.nl/en/publications/83830297-0964-4800-8a76-7a16cdeee03d

An artificial intelligence method using 18F-FDG PET maximum intensity projections to predict 2-year time-to-progression in diffuse large B-cell lymphoma patients

Autor: Maria C. Ferrández, Sandeep S. V. Golla, Jakoba J. Eertink, Bart M. de Vries, Pieternella. J. Lugtenburg, Sanne E. Wiegers, Gerben J. C. Zwezerijnen, Simone Pieplenbosch, Lars Kurch, Andreas Hüttmann, Christine Hanoun, Ulrich Dührsen, Henrica C.W. de Vet, Josée M. Zijlstra, Ronald Boellaard

Convolutional neural networks (CNNs) may improve response prediction in diffuse large B-cell lymphoma (DLBCL). The aim of this study was to investigate the feasibility of a CNN using maximum intensity projection (MIP) images from 18F-fluorodeoxygluco

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::08f16f766b6e93d8f57d032fbe9aa2ec
https://doi.org/10.21203/rs.3.rs-2761494/v1

Intensified cytarabine dose during consolidation in AML patients under 65 years is not associated with survival benefit: real-world data from the German SAL-AML registry

Autor: Maher Hanoun, Leo Ruhnke, Michael Kramer, Christine Hanoun, Kerstin Schäfer-Eckart, Björn Steffen, Tim Sauer, Stefan Krause, Christoph Schliemann, Jan-Henrik Mikesch, Martin Kaufmann, Mathias Haenel, Edgar Jost, Tim Bruemmendorf, LArs Fransecky, Sabrina Kraus, Hermann Einsele, Dirk Niemann, Andreas Neubauer, Johannes Kullmer, Ruth Seggewiss-Bernhard, Martin Goerner, Gerhard Held, Ulrich Kaiser, Sebastian Scholl, Andreas Hochhaus, Hans Reinhardt, Uwe Platzbecker, Claudia Baldus, Carsten Müller-Tidow, Martin Bornhäuser, Hubert Serve, Christoph Röllig

Higher doses of cytarabine appear to improve long-term outcome in acute myeloid leukemia (AML), in particular for younger patients. To this end, the optimal dosage of single agent cytarabine in consolidation therapy remains elusive. Here, we assessed

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b3efddf187af967c6dd3436ccf5d34d1
https://doi.org/10.21203/rs.3.rs-1704919/v1